We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Silver Nanocluster DNA Probes Detect MicroRNA

By LabMedica International staff writers
Posted on 23 Oct 2012
A method that uses inexpensive technology and simple analytical apparatuses promises to trim days off the laboratory work done to diagnose diseases. More...


Any disease that assails a patient leaves genetic clues all over the victim, and because the profiles of micro ribonucleic acid (miRNA) vary by type of cancer, finding it proves beyond a reasonable doubt what is making the patient sick.

A chemist and a biologist from University of Copenhagen (Denmark) invented the detection method, which exploits a natural quality of genetic material. Together they figured out how to attach the light emitting molecules to DNA sensors for miRNA detection. When these luminous DNA-strands stick with microRNA-strands, their light is quenched, giving a very visible indication that the target miRNA is present in the sample.

A single DNA strand is made up of molecules, so called bases, ordered in a unique combination. When two strands join to form their famous double helix, they do so by sticking to complementary copies of themselves. Likewise, strands tailored to match particular miRNAs will stick to the real thing with uncanny precision.

The scientists tested their Silver Nano Cluster DNA probes with eight different types of genetic material and found that they work outright with six of them. They then fathomed how to fix the ones that did not perform. This indicates that their method will work in the detection of almost all types of miRNAs, also in all likelihood for cancer related miRNAs. The most widespread current miRNA detection method requires some 48 hours of laboratory work from raw samples. The new method can do the same job of detection within a maximum of six hours.

Tom Vosch, PhD, from the Department of Chemistry and senior coauthor of the study said, "We invented a probe that emits light only as long as the sample is clean. That is an unusually elegant and easy way to screen for a particular genetic target." The study was published on September 4, 2012, in the American Chemical Society journal ACSNano.

Related Links:

University of Copenhagen



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.